Research programme: T-type calcium channel antagonists - Cavion

Drug Profile

Research programme: T-type calcium channel antagonists - Cavion

Alternative Names: TTL-1177

Latest Information Update: 29 Sep 2016

Price : $50

At a glance

  • Originator Tau Therapeutics
  • Developer Cavion
  • Class Small molecules
  • Mechanism of Action T type calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Neuropathic pain

Most Recent Events

  • 29 Sep 2016 Preclinical development is ongoing for Cancer in USA
  • 29 Sep 2016 Research is ongoing for Neuropathic-pain in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top